v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue        
Total revenue $ 187,546   $ 340,001 $ 4,255
Total revenue   $ (21,172)    
Cost of revenues 319,889 0 562,214 0
Operating expenses        
Selling, general and administrative 2,593,671 2,377,866 4,842,237 4,687,030
Research and development 241,966 1,428,762 902,428 3,726,143
Total operating expenses 2,835,637 3,806,628 5,744,665 8,413,173
Loss from operations (2,967,980) (3,827,800) (5,966,878) (8,408,918)
Other (expense) income (14,793) (188,683) (15,784) 14,128
Net loss (2,982,773) (4,016,483) (5,982,662) (8,394,790)
Foreign currency translation adjustments 2,225 12,893 46,768 25,983
Comprehensive loss $ (2,980,548) $ (4,003,590) $ (5,935,894) $ (8,368,807)
Loss per common share - basic (in usd per share) $ (0.20) $ (0.45) $ (0.41) $ (0.95)
Loss per common share - diluted (in usd per share) $ (0.20) $ (0.45) $ (0.41) $ (0.95)
Weighted average number of shares outstanding:        
Basic (in shares) 14,889,832 8,871,155 14,707,347 8,815,414
Diluted (in shares) 14,889,832 8,871,155 14,707,347 8,815,414
Research and development services and royalty revenue        
Revenue        
Total revenue $ 187,546   $ 340,001 $ 4,255
Total revenue   $ (21,172)